Mirum, Fulcrum file for IPOs
On Friday, Mirum and Fulcrum each filed to raise up to $86.3 million in NASDAQ IPOs.
Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched in November with a $120 million series A round led by New Enterprise Associates. The biotech has a license from Shire plc to a pair of SLC10A2 inhibitors to treat liver diseases (see "Mirium Launches with Liver Disease Candidates from Shire"). ...